The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuddihy, Grace, Wasan, Ellen K., Di, Yunyun, Wasan, Kishor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470859/
https://www.ncbi.nlm.nih.gov/pubmed/30813569
http://dx.doi.org/10.3390/pharmaceutics11030099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470859/
https://www.ncbi.nlm.nih.gov/pubmed/30813569
http://dx.doi.org/10.3390/pharmaceutics11030099

Ejemplares similares